{"url_path":"/sec/bdtx/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1701541/0001104659-26-065254-index.html","accession_number":"0001104659-26-065254","cik":"0001701541","ticker":"BDTX","issuer_name":"Black Diamond Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701541/0001104659-26-065254-index.html","primary_entity_key":"0001701541","primary_entity_name":"Black Diamond Therapeutics, Inc."},"word_count":87,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits:\n\n \n\n**Exhibit No.**\n \n**Description**\n\n[99.1](tm2615293d1_ex99-1.htm)\n \n[Press Release issued by Black Diamond Therapeutics, Inc. dated May 21, 2026.](tm2615293d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nBlack Diamond Therapeutics, Inc.\n\n \n \n \n\nDate: May 21, 2026\nBy:\n/s/ Brent Hatzis-Schoch\n\n \n \nBrent Hatzis-Schoch\n\n \n \nChief Operating Officer and General Counsel"}